Drug discontinuation: Aprepitant Oral Powder for Suspension (EMEND)
FDA lists 1 presentation as To Be Discontinued. Companies: Merck Sharp & Dohme LLC.
- Published by source
- 2026-04-08
- First seen by Reality Radar
- 2026-10-22
- Last verified
- 2026-10-22
Affected
- Manufacturer
- Merck Sharp & Dohme LLC
- Products
- Aprepitant Oral Powder for Suspension EMEND
Whether your exact unit is affected depends on the model, serial number and region in the official notice.
What the official notice says
Risk: To Be Discontinued
Remedy / actions:
- To be discontinued in approximately early-September 2026.
Is this affecting you?
Add what you own or use and Reality Radar will tell you when official changes match it — with evidence and next steps.
Sources
- openFDA Drug Shortages Tier A · official published 2026-04-08
Evidence ledger
Every piece of evidence we store is appended to a public hash chain, so later edits are detectable. Anyone can re-verify it.
| Entry | Kind | Observed | Evidence hash | Entry hash |
|---|---|---|---|---|
| #1046 | new | 2026-10-22 | 8e475c51669c…ac643a | 51ecb94494de…f28c64 |
Chain head: #1094 edf3be25ec2e…478842